JPWO2022138909A1 - - Google Patents

Info

Publication number
JPWO2022138909A1
JPWO2022138909A1 JP2022571676A JP2022571676A JPWO2022138909A1 JP WO2022138909 A1 JPWO2022138909 A1 JP WO2022138909A1 JP 2022571676 A JP2022571676 A JP 2022571676A JP 2022571676 A JP2022571676 A JP 2022571676A JP WO2022138909 A1 JPWO2022138909 A1 JP WO2022138909A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022571676A
Other versions
JP7359973B2 (ja
JPWO2022138909A5 (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2022138909A1 publication Critical patent/JPWO2022138909A1/ja
Publication of JPWO2022138909A5 publication Critical patent/JPWO2022138909A5/ja
Priority to JP2023166660A priority Critical patent/JP7432053B2/ja
Application granted granted Critical
Publication of JP7359973B2 publication Critical patent/JP7359973B2/ja
Priority to JP2024014953A priority patent/JP7484030B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16Cyclodextrin; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02Oxygen as only ring hetero atoms
    • C12P17/06Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Physiology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Botany (AREA)
JP2022571676A 2020-12-24 2021-12-24 エクオールの経口による血中吸収性を向上させる方法及びβ-シクロデキストリンからなるエクオールの血中吸収促進剤 Active JP7359973B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023166660A JP7432053B2 (ja) 2020-12-24 2023-09-28 シクロデキストリンにエクオールが包接された包接体を含有するエクオール吸収性組成物
JP2024014953A JP7484030B2 (ja) 2020-12-24 2024-02-02 シクロデキストリンにエクオールが包接された包接体の製造方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020215247 2020-12-24
JP2020215247 2020-12-24
PCT/JP2021/048167 WO2022138909A1 (ja) 2020-12-24 2021-12-24 シクロデキストリンにエクオールが包接された包接体、該包接体を含有するエクオール吸収性組成物、及びこれらの製造方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023166660A Division JP7432053B2 (ja) 2020-12-24 2023-09-28 シクロデキストリンにエクオールが包接された包接体を含有するエクオール吸収性組成物

Publications (3)

Publication Number Publication Date
JPWO2022138909A1 true JPWO2022138909A1 (ja) 2022-06-30
JPWO2022138909A5 JPWO2022138909A5 (ja) 2023-08-18
JP7359973B2 JP7359973B2 (ja) 2023-10-11

Family

ID=82158029

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022571676A Active JP7359973B2 (ja) 2020-12-24 2021-12-24 エクオールの経口による血中吸収性を向上させる方法及びβ-シクロデキストリンからなるエクオールの血中吸収促進剤
JP2023166660A Active JP7432053B2 (ja) 2020-12-24 2023-09-28 シクロデキストリンにエクオールが包接された包接体を含有するエクオール吸収性組成物
JP2024014953A Active JP7484030B2 (ja) 2020-12-24 2024-02-02 シクロデキストリンにエクオールが包接された包接体の製造方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023166660A Active JP7432053B2 (ja) 2020-12-24 2023-09-28 シクロデキストリンにエクオールが包接された包接体を含有するエクオール吸収性組成物
JP2024014953A Active JP7484030B2 (ja) 2020-12-24 2024-02-02 シクロデキストリンにエクオールが包接された包接体の製造方法

Country Status (3)

Country Link
US (1) US20240082424A1 (ja)
JP (3) JP7359973B2 (ja)
WO (1) WO2022138909A1 (ja)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012135218A (ja) * 2010-12-24 2012-07-19 Daicel Corp エクオールの製造法、エクオール産生組成物、食品、食品添加物及び医薬品
WO2013058303A1 (ja) * 2011-10-18 2013-04-25 ラクオリア創薬株式会社 医薬組成物
JP2020058319A (ja) * 2018-10-12 2020-04-16 株式会社ダイセル 6−ヒドロキシダイゼインの製造方法
JP2020092690A (ja) * 2018-12-07 2020-06-18 学校法人東京理科大学 エクオール誘導体の産生のための組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006111534A (ja) 2004-10-12 2006-04-27 Bio Taxol:Kk クルクミン水溶液の製造方法
CN102726683B (zh) 2005-12-06 2015-04-01 大塚制药株式会社 含雌马酚的大豆胚轴发酵物
CN102919739B (zh) 2007-06-13 2014-07-02 大塚制药株式会社 含雌马酚的提取物、其制备方法、雌马酚的提取方法及含雌马酚的食品
WO2020090137A1 (ja) 2018-10-30 2020-05-07 太陽化学株式会社 容器詰飲料
JP7451185B2 (ja) 2019-01-22 2024-03-18 株式会社ダイセル 新規微生物およびその利用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012135218A (ja) * 2010-12-24 2012-07-19 Daicel Corp エクオールの製造法、エクオール産生組成物、食品、食品添加物及び医薬品
WO2013058303A1 (ja) * 2011-10-18 2013-04-25 ラクオリア創薬株式会社 医薬組成物
JP2020058319A (ja) * 2018-10-12 2020-04-16 株式会社ダイセル 6−ヒドロキシダイゼインの製造方法
JP2020092690A (ja) * 2018-12-07 2020-06-18 学校法人東京理科大学 エクオール誘導体の産生のための組成物

Also Published As

Publication number Publication date
JP7359973B2 (ja) 2023-10-11
JP7484030B2 (ja) 2024-05-15
JP2023165927A (ja) 2023-11-17
US20240082424A1 (en) 2024-03-14
JP7432053B2 (ja) 2024-02-15
WO2022138909A1 (ja) 2022-06-30
JP2024036485A (ja) 2024-03-15

Similar Documents

Publication Publication Date Title
BR112023005462A2 (ja)
BR112023012656A2 (ja)
BR102021015500A2 (ja)
BR102021007058A2 (ja)
BR102020022030A2 (ja)
BR112023011738A2 (ja)
BR112023016292A2 (ja)
JPWO2022138909A1 (ja)
BR112023004146A2 (ja)
BR112023011610A2 (ja)
BR102021016176A2 (ja)
BR102021015566A2 (ja)
BR102021015450A8 (ja)
BR202021015276U2 (ja)
BR102021015247A2 (ja)
BR102021015220A2 (ja)
BR102021014056A2 (ja)
BR102021014044A2 (ja)
BR102021013929A2 (ja)
BR102021012571A2 (ja)
BR102021012230A2 (ja)
BR102021012107A2 (ja)
BR102021012003A2 (ja)
BR102021010467A2 (ja)
BR102021009555A2 (ja)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230620

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20230620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230810

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230829

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230928

R150 Certificate of patent or registration of utility model

Ref document number: 7359973

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150